Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ono Pharmaceutical
Biotech
Ono’s Deciphera drops early-stage solid tumor drug
Ono said the pan-RAF inhibitor has been scrapped for reasons unrelated to safety or efficacy.
Darren Incorvaia
Mar 3, 2026 7:47pm
Ono's BMS-partnered IO drug passes phase 2 gastric cancer test
Oct 9, 2025 10:10am
Ono Pharma lays off 83 staffers at Cambridge site
Apr 29, 2025 1:56pm
Ono pays $280M upfront for Ionis' phase 2 blood cancer med
Mar 12, 2025 6:30am
Merck KGaA tumor trial hits goal, teeing up Daiichi, Ono rivalry
Nov 12, 2024 4:46am
Ono inks $700M biobuck deal to bag preclinical LigaChem ADC
Oct 10, 2024 9:40am